Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ravi M. Shah"'
Autor:
Stephanie A. Maier, Imran Ahmad, Tobias Berg, Susan Berrigan, Mahmoud Elsawy, Alejandro Garcia-Horton, Wilson Lam, Alix Lapworth, Luciana Melo Garcia, Ravi M. Shah, Ram Vasudevan Nampoothiri, Jean-Sébastien Delisle
Publikováno v:
Current Oncology, Vol 31, Iss 6, Pp 2918-2951 (2024)
On behalf of Cell Therapy Transplant Canada (CTTC), we are pleased to present the Abstracts of the CTTC 2023 Annual Conference. The conference was held in-person, 31 May–2 June 2023, in Halifax, Nova Scotia at the Westin Nova Scotian hotel. Poster
Externí odkaz:
https://doaj.org/article/280775e1430347e8b7e188c2804e3b2c
Autor:
Ravi M. Shah, Amita Trehan
Publikováno v:
Pediatric Hematology Oncology Journal, Vol 6, Iss 2, Pp 105-109 (2021)
The management of immune thrombocytopenic purpura (ITP) in children show great variation among physicians and centers. American Society of Hematology (ASH) has recently (2019) come up with updated guidance on the management of ITP in children and adu
Externí odkaz:
https://doaj.org/article/4f02a9512f894dd4b3a5a5388c053f6a
Publikováno v:
Contemporary Bone Marrow Transplantation ISBN: 9783319649382
Contemporary Bone Marrow Transplantation
Contemporary Bone Marrow Transplantation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61aaddabaffecd09e4b5a03e56395a34
https://doi.org/10.1007/978-3-030-36358-1_11
https://doi.org/10.1007/978-3-030-36358-1_11
Autor:
Ravi M, Shah
Publikováno v:
Bone marrow transplantation. 56(7)
The barriers to HLA-mismatched or haploidentical hematopoietic stem cell transplantation (HSCT), namely GvHD and graft failure, have been overcome with novel transplant platforms. Post-transplant Cyclophosphamide (PTCy) is widely available, feasible
Autor:
Ravi M, Shah, Tony H, Truong, Michel T, Leaker, Nicola A M, Wright, Doan, Le, MacGregor, Steele, Aisha A K, Bruce, Sunil, Desai, Gregory M T, Guilcher, Victor, Lewis
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 26(10)
Various reduced-intensity conditioning regimens are in use for allogeneic hematopoietic cell transplant (HSCT) in patients with idiopathic severe aplastic anemia (SAA). We describe the use of fludarabine, Campath, and low-dose cyclophosphamide (FCC
Publikováno v:
Journal of Clinical Immunology. 37:419-421
Publikováno v:
Medicine & Science in Sports & Exercise. 52:682-682
Autor:
Ravi M, Shah, Reem, Elfeky, Zohreh, Nademi, Waseem, Qasim, Persis, Amrolia, Robert, Chiesa, Kanchan, Rao, Giovanna, Lucchini, Juliana M F, Silva, Austen, Worth, Dawn, Barge, David, Ryan, Jane, Conn, Andrew J, Cant, Roderick, Skinner, Intan Juliana, Abd Hamid, Terence, Flood, Mario, Abinun, Sophie, Hambleton, Andrew R, Gennery, Paul, Veys, Mary, Slatter
Publikováno v:
The Journal of allergy and clinical immunology. 141(4)
Allogeneic hematopoietic stem cell transplantation (HSCT) is used as a therapeutic approach for primary immunodeficiencies (PIDs). The best outcomes have been achieved with HLA-matched donors, but when a matched donor is not available, a haploidentic